Why the study?
Does a single oral dose of flosequinan improve hemodynamic parameters in patients with severe heart failure?
Population
29 patients with severe heart failure, mean age 57.3, 21 male, 8 female, in Japan.
Design
Cohort, open-label
Follow-up
24 hours
Key result
A single 100 mg oral dose of flosequinan significantly improved hemodynamics in patients with severe heart failure, including a 7.7 mmHg (41%) decrease in pulmonary capillary wedge pressure and a 16% increase in cardiac index.
Authors
Loading...
No practice change from this Level 3 cohort; leaves open whether flosequinan improves outcomes in severe HF.
Does a single oral dose of flosequinan improve hemodynamic parameters in patients with severe heart failure?
Mean Difference: -7.7
p-value: p=<0.001
A single 100 mg oral dose of flosequinan exerts sustained beneficial hemodynamic effects, including increased cardiac index and decreased filling pressures, for 24 hours in patients with severe heart failure.
Hirosawa et al. (1992) studied Severe heart failure (n=29). Flosequinan vs. Baseline was evaluated on Pulmonary capillary wedge pressure (PCWP) (-7.7 mmHg, p=<0.001). A single 100 mg oral dose of flosequinan significantly improved hemodynamics in patients with severe heart failure, including a 7.7 mmHg (41%) decrease in pulmonary capillary wedge pressure and a 16% increase in cardiac index.